"checkpoint inhibitor associated pneumonia" trang 5 - tải miễn phí từ tailieuXANH
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)
8    68    0
‘DURVIT’: A phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: Safety, toxicity and effect on the primary tumour and lymph node microenvironment

‘DURVIT’: A phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: Safety, toxicity and effect on the primary tumour and lymph node microenvironment
8    64    0
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
6    65    0
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma

Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma
7    65    0
Immunotherapy for non-small cell lung cancers: Biomarkers for predicting responses and strategies to overcome resistance

Immunotherapy for non-small cell lung cancers: Biomarkers for predicting responses and strategies to overcome resistance
10    99    0
Immunotherapy and associated immunerelated adverse events at a large UK centre: A mixed methods study

Immunotherapy and associated immunerelated adverse events at a large UK centre: A mixed methods study
11    48    0
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
10    46    0
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
9    69    0
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
11    50    0
Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation

Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation
11    58    0
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: Study protocol of the TRADE-hypo trial

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: Study protocol of the TRADE-hypo trial
10    60    0
Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer

Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer
8    52    0
High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients

High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients
7    42    0
Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: Conformational changes of the BCloop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab

Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: Conformational changes of the BCloop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab
12    57    0
Response to pembrolizumab in a patient with primary lung adenocarcinoma originated from indium lung

Response to pembrolizumab in a patient with primary lung adenocarcinoma originated from indium lung
5    55    1
Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation
8    56    1
Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments

Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments
12    40    1
A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer

A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer
12    45    1
The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy
11    31    1
A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
13    45    1
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.